DesiletsA, RepettoM, YangSR, et al.RET-altered cancers—A tumor-agnostic review of biology, diagnosis and targeted therapy activity. Cancers (Basel), 2023:15(16); doi: 10.3390/cancers15164146
2.
AddeoA, Miranda-MoralesE, den HollanderP, et al.RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives. Pharmacol Ther, 2023; 242:108344; doi: 10.1016/j.pharmthera.2023.108344
3.
WirthLJ, ShermanE, RobinsonB, et al.Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med, 2020; 383(9):825–835; doi: 10.1056/NEJMoa2005651
4.
SubbiahV, HuMI, WirthLJ, et al.Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): A multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol, 2021; 9(8):491–501; doi: 10.1016/S2213-8587(21)00120-0
5.
HadouxJ, EliseiR, BroseMS, et al.Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer. N Engl J Med, 2023; 389(20):1851–1861; doi: 10.1056/NEJMoa2309719
6.
MatroneA, GambaleC, PreteA, et al.Sporadic medullary thyroid carcinoma: Towards a precision medicine. Front Endocrinol (Lausanne), 2022; 13:864253; doi: 10.3389/fendo.2022.864253
7.
TsangV, GillA, GildM, et al.Selpercatinib treatment of RET-mutated thyroid cancers is associated with gastrointestinal adverse effects. J Clin Endocrinol Metab, 2022; 107(9):e3824–e3829; doi: 10.1210/clinem/dgac337
8.
PreteA, GambaleC, CappagliV, et al.Chylous effusions in advanced medullary thyroid cancer patients treated with selpercatinib. Eur J Endocrinol, 2022; 187(6):905–915; doi: 10.1530/EJE-22-0643
9.
VoznesenskyM, AnnamK, KrederKJ. Understanding and managing erectile dysfunction in patients treated for cancer. J Oncol Pract, 2016; 12(4):297–304; doi: 10.1200/JOP.2016.010678
10.
LevineLA, KlonerRA. Importance of asking questions about erectile dysfunction. Am J Cardiol, 2000; 86(11):1210–1213, A5; doi: 10.1016/s0002-9149(00)01204-2
11.
MaM, YuB, QinF, et al.Current approaches to the diagnosis of vascular erectile dysfunction. Transl Androl Urol, 2020; 9(2):709–721; doi: 10.21037/tau.2020.03.10
12.
BuvatJ, MontorsiF, MaggiM, et al.Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med, 2011; 8(1):284–293; doi: 10.1111/j.1743-6109.2010.01956.x
13.
GrecoEA, SperaG, AversaA. Combining testosterone and PDE5 inhibitors in erectile dysfunction: Basic rationale and clinical evidences. Eur Urol, 2006; 50(5):940–947; doi: 10.1016/j.eururo.2006.06.049
14.
CampbellJD, BurnettAL. Neuroprotective and nerve regenerative approaches for treatment of erectile dysfunction after cavernous nerve injury. Int J Mol Sci, 2017:18(8); doi: 10.3390/ijms18081794
15.
MengX, LindahlM, HyvonenME, et al.Regulation of cell fate decision of undifferentiated spermatogonia by GDNF. Science, 2000; 287(5457):1489–1493; doi: 10.1126/science.287.5457.1489
16.
KawaiK, TakahashiM. Intracellular RET signaling pathways activated by GDNF. Cell Tissue Res, 2020; 382(1):113–123; doi: 10.1007/s00441-020-03262-1
17.
HuangSA, LieJD. Phosphodiesterase-5 (PDE5) inhibitors in the management of erectile dysfunction. P T, 2013; 38(7):407–419.
18.
RingBJ, PattersonBE, MitchellMI, et al.Effect of tadalafil on cytochrome P450 3A4-mediated clearance: Studies in vitro and in vivo. Clin Pharmacol Ther, 2005; 77(1):63–75; doi: 10.1016/j.clpt.2004.09.006
